 CAMBRIDGE, Mass. BEIJING BASEL, Switzerland--BUSINESS WIRE--- BGNE BTKi--BeiGene NASDAQ: BGNE; HKEX: 06160; SSE: 688235, a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that clinical results, as well as biomarker data, from its immuno-oncology program in solid tumors will be presented at the American Academy for Cancer Research AACR Annual Meeting 2022. The AACR 